No Data
No Data
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Sinopharm is consistent (000028): The performance is in line with expectations, and the distribution sector has achieved steady growth
The results for the first quarter of 2024 are in line with our expectations for the first quarter of 2024: the company achieved operating income of 19.090 billion yuan, an increase of 2.16% year on year; net profit to mother was 389 million yuan, an increase of 7 percent year on year.
Sinopharm is consistent (000028): Distribution is growing steadily, and retail growth is slowing down under a high base
Guide to this report: 2024Q1 distribution has maintained steady growth, and retail sales have declined due to the decline in high base growth, and the industry has contributed steady profits. With improvements in internal business quality and product restructuring, the company's net interest rate is expected to continue to rise. Key investment points: maintaining and increasing holdings
Sinopharm's consistent (000028) 2024Q1 performance review: steady distribution growth, retail growth decelerates under a high retail base
Guide to this report: 2024Q1 distribution has maintained steady growth, and retail sales have declined due to the decline in high base growth, and the industry has contributed steady profits. With improvements in internal business quality and product restructuring, the company's net interest rate is expected to continue to rise. Key investment points: maintaining and increasing holdings
Sinopharm is consistent (000028): stable growth in the 1Q distribution sector and improved profitability
1Q24 performance grew steadily, and profitability continued to improve the company's 1Q24 operating income/net profit attributable to mother/net profit of 190.90/3.89/370 million yuan, +2.16%/+7.33% year-on-year
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates decline
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates declined during the period; 2) the distribution business grew steadily and the profitability of the retail business increased; 3) National University Pharmacy increased its store expansion efforts and actively innovated online and offline multi-channel businesses. (Mainichi Keizai Shimbun)
No Data